// App-Quantinova.ai

THU0299 (2018) : An integrated analysis of changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis across phase 3 and long-term extension studies

Researchers

Presenter

  • D.D. Gladman

Principal Investigators

  • C. Charles-Schoeman

  • I.B. McInnes

  • D.J. Veale

  • B. Thiers

  • D. Graham

  • C. Wang

  • T.V. Jones

  • R. Wolk

  • R. DeMasi

Medical Centers

  • Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada

  • University of Southern California, Los Angeles, CA

  • EScience, University of Glasgow, Glasgow, UK

  • St Vincents University Hospital and University College Dublin, Dublin, Ireland

  • Medcl Univ of South Carolina, Charleston, SC

  • Pfizer, Groton, CT

  • Pfizer Inc, Collegeville, PA

Locations

  • Canada

  • United States

  • United Kingdom

  • Ireland

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

  • Musculoskeletal

  • Cardiovascular (CVS)

Disease

  • Psoriatic arthritis

  • Hypertension

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Tasocitinib

  • Adalimumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT01877668

  • NCT01882439]

  • NCT01976364]

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved